What A Whiz! Takeda Spins Off Discovery Op Axcelead Into New Fund
Executive Summary
Takeda has spun off into a new joint investment fund selected drug discovery operations in Japan that had been shifted to the new Axcelead business last year, further honing its focus ahead of the Shire acquisition and in a move to foster a more effective early-stage ecosystem in the country.
You may also be interested in...
Takeda To Press On With Core R&D Strategy Post-Shire
Takeda continues to pursue the transformation of its R&D activities, which has already led to expansion of the pipeline, but will continue with core strategies including partnering even after the huge Shire acquisition.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.